The European Medicines Agency (EMA) wants to decide today, Monday, on the approval of the corona vaccine from the US pharmaceutical company Novavax. An extraordinary meeting will be held on the Nuvaxovid vaccine developed by Novavax. The company applied for EU approval back in November. Nuvaxovid is a recombinant protein vaccine.
SN/APA/GETTY IMAGES NORTH AMERICA/K
Effectiveness of around 90 percent
According to the pharmaceutical company, the agent has an effectiveness of around 90 percent. It was developed using well-established methods that are already being used against a number of other diseases. All vaccines against SARS-CoV-2 approved so far in the EU use novel technologies. The two from BioNTech / Pfizer and Moderna are mRNA vaccines, while AstraZeneca and Johnson & Johnson are vector vaccines. When the dead vaccine from Valneva of the Austro-French biotechnology company will be approved is unclear. That could take several weeks if not months. Traditional inactivated vaccines are of particular interest to people who have reservations about immunization with mRNA vaccines or vector vaccines.
Accessed on December 19, 2021 at 11:45 am on https://www.sn.at/panorama/international/ema-will-ueber-corona-impfstoff-novavax-entscheiden-114269551